Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: Role in foam cell formation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 2 56-2, 2004, Pages

  Smirnova, I V ^a   Kajstura, M ^a   Sawamura, T ^b   Goligorsky, M S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Atherogenesis; Lectin like oxidized low density lipoprotein receptor 1; Nitric oxide; Renal failure

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; LECTIN LIKE OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; BIOACCUMULATION; BIOSYNTHESIS; CELL INFILTRATION; CELL LEVEL; CELL ULTRASTRUCTURE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; FOAM CELL; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERNALIZATION; INTIMA; LEUKEMIA CELL; LIPID STORAGE; MACROPHAGE ACTIVATION; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; WESTERN BLOTTING;

ARGININE; CELL DIFFERENTIATION; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FOAM CELLS; FREE RADICAL SCAVENGERS; HL-60 CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; METALLOPORPHYRINS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; RECEPTORS, CELL SURFACE; RECEPTORS, LDL; RNA, SMALL INTERFERING; UMBILICAL VEINS; UP-REGULATION;

EID: 3242690619     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00822.2003     Document Type: Article

References (60)

1. Achan V, Broadhead M, Malaki M, Whitley GS, Leiper J, MacAllister R, and Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003.
2. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 8: 71-86, 2003.
3. Boger RH and Bode-Boger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 26: 539-545, 2000.
4. Boger RH, Bode-Boger SM, Kienke S, Stan AC, Nafe R, and Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 136: 67-77, 1998.
5. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, and Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36: 2287-2295, 2000.
6. Boger RH, Vallance, P, and Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 4: 1-3, 2003.
7. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, and Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethionine-dependent methyltransferases. Circ Res 87: 99-105, 2000.
8. Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, and Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52: 652-657, 2003.
9. Closs EI, Basha FZ, Habermeier A, and orstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73, 1997.
10. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, and Cooke JP. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20: 1040-1046, 2000.
11. Chen M, Masaki T, and Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95: 89-100, 2002.
12. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, and Sawamura T. The binding of oxidized low-density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276: 13750-13755, 2001.
13. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20: 2032-2037, 2000.
14. De Villiers WJ and Smart EJ. Macrophage scavenger receptors and foam cell formation. J Leukoc Biol 66: 740-746, 1999.
15. Draude G and Lorenz RL. TGF-betal downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages. Am J Physiol Heart Circ Physiol 278: H1042-H1048, 2000.
16. Fliser D, Kielstein JT, Haller H, and Bode-Boger SM. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl 37-40, 2003.
17. Gotoh T, Oyadomari S, Mori K, and Mori M. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP. J Biol Chem 277: 12343-12350, 2002.
18. Hayashida K, Kume N, Minami M, and Kita T. Lectin-like oxidized LDL receptor-1 (LOX-1) supports adhesion of mononuclear leukocytes and a monocyte-like cell line THP-1 cells under static and flow conditions. FEBS Lett 511: 133-138, 2002.
19. Heinloth A, Brune B, Fischer B, and Galle J. Nitric oxide prevents oxidised LDL-induced p53 accumulation, cytochrome c translocation, and apoptosis in macrophages via guanylate cyclase stimulation. Atherosclerosis 162: 93-101, 2002.
20. Hunter GC, Henderson AM, Westerband A, Kobayashi H, Suzuki F, Yan ZQ, Sirsjo A, Putnam CW, and Hansson GK. The contribution of inducible nitric oxide and cytomegalovirus to the stability of complex carotid plaque. J Vasc Surg 30: 36-50, 1999.
21. Ito S. Nitric oxide in the kidney. Curr Opin Nephrol Hypertens 4: 23-30, 1995.
22. Jankowski J, van der Giet M, Jankowski V, Schimidt S, Heirneler M, Mahn B, Giebing G, Tölle M, Luftmann H, Schlüter H, Zidek W, and Tepel M. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 112: 256-264, 2003.
23. Jessup W and Dean RT. Autoinhibition of mur ine macrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis 101: 145-155, 1993.
24. Jessup W and Kritharides L. Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11: 473-481, 2000.
25. Jouni ZE, Winzerling JJ, and McNamara DJ. 1,25-Dihydroxyvitamin D3-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism. Atherosclerosis 117: 125-138, 1995.
26. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, and Kita T. Expression of lectinlike oxidized low-density lipoprotein receptor-I in human atherosclerotic lesions. Circulation 99: 3110-3117, 1999.
27. Kelm M. The [L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 5: 80-86, 2003.
28. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, and Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107: 1891-1895, 2003.
29. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, and Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 33: 370-375, 2003.
30. Kimura C, Oike M, Ohnaka K, Nose Y, and Ito Y. Constitutive nitric oxide production in bovine aortic and brain microvascular endothelial cells: a comparative study. J Physiol 554: 721-730, 2004. First published November 14, 2003; 10.1113/jphysiol.2003.057059.
31. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, Arai H, and Yokode M. Role of oxidized LDL in atherosclerosis. Ann NYAcad Sci 947: 199-206, 2001.
32. Kita T, Kume N, Yokode M, Ishii K, Arai H, Horiuchi H, Moriwaki H, Minami M, Kataoka H, and Wakatsuki Y. Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann NY Acad Sci 902: 95-102, 2000.
33. Klinge JM, Topf HG, Trusen B, Rauh M, Rascher W, and Dotsch J. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide. Crit Care Med 31: 2010-2014, 2003.
34. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, and Bult H. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol 23: 440-446, 2003.
35. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, and Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343: 531-535, 1990.
36. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, and Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem 70: 2446-2453, 1998.
37. Kosaka S, Takahashi S, Masamura K, Kanehara H, Sakai J, Tohda G, Okada E, Oida K, Iwasaki T, Hattori H, Kodama T, Yamamoto T, and Miyamori I. Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages. Circulation 103: 1142-1147, 2001.
38. Kruth HS, Huang W, Ishii I, and Zhang WY. Macrophage foam cell formation with native low-density lipoprotein. J Biol Chem 277: 34573-34580, 2002.
39. Kuhlencordt PJ, Chen J, Han F, Astern J, and Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103: 3099-3104, 2001.
40. Kume N and Kita T. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol 12: 419-423, 2001.
41. Kume N, Moriwaki H, Kataoka H, Minami M, Murase T, Sawamura T, Masaki T, and Kita T. Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells. Ann NY Acad Sci 902: 323-327, 2000.
42. Li AC and Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242, 2002.
43. London GM and Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51: 1678-1695, 1997.
44. Lougheed M, Moore ED, Scriven DR, and Steinbrecher UP. Uptake of oxidized LDL by macrophages differs from that of acetyl LDL and leads to expansion of an acidic endolysosomal compartment. Arterioscler Thromb Vasc Biol 19: 1881-1890, 1999.
45. MacAllister RJ and Vallance P. Endogenous inhibitors of nitric oxide synthesis: how important are they? Exp Nephrol 6: 195-199, 1998.
46. MacAllister RJ, Whitley GS, and Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742, 1994.
47. Mehta JL and Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol 39: 1429-1435, 2002.
48. Mehta JL, Li DY, Chen HJ, Joseph J, and Romeo F. Inhibition of LOX-I by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 289: 857-861, 2001.
49. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, and Holtz J. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100: 899-902, 1999.
50. Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E, Sawamura T, Masaki T, and Kita T. Expression of lectin-like oxidized low-density lipoprotein receptor-I in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett 440: 29-32, 1998.
51. Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, Nishi E, Masaki T, and Kita T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 18: 1541-1547, 1998.
52. Nicholson AC, Han J, Febbraio M, Silversterin RL, and Hajjar DP. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann NY Acad Sci 947: 224-228, 2001.
53. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Grego F, and Pauletto P. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol 16: 11-20, 2003.
54. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, and Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 386: 73-77, 1997.
55. Vainio S and Ikonen E. Macrophage cholesterol transport: a critical player in foam cell formation. Ann Med 35: 146-155, 2003.
56. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358: 2096-2097, 2001.
57. Vallance P, Leone A, Calver A, Collier J, and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
58. WAFI/CIPI. J Leukoc Biol 68: 916-922, 2000.
59. Yates MT, Lambert LE, Whitten JP, McDonald I, Mano M, Ku G, and Mao SJ. A protective role for nitric oxide in the oxidative modification of low-density lipoproteins by mouse macrophages. FEBS Lett 309: 135-138, 1992.
60. Zingg JM, Ricciarelli R, and Azzi A. Scavenger receptors and modified lipoproteins: fatal attractions? IUBMB Life 49: 397-403, 2000.